	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	267.07	396.63	344.64	407.13	546.89	403.35	372.02	898.25	689.31	577.21	747.45	751.59	770.24	809.73	927.11	1,005.22
Cost of Operating Revenue	169.18	226.60	207.71	222.63	310.05	241.83	240.81	668.28	458.44	354.28	416.56	427.12	418.93	454.43	472.78	482.84
Gross Profit	97.89	170.03	136.94	184.50	236.85	161.51	131.21	229.97	230.87	222.93	330.89	324.47	351.32	355.29	454.34	522.38
Gross Margin	36.7	42.9	39.7	45.3	43.3	40.0	35.3	25.6	33.5	38.6	44.3	43.2	45.6	43.9	49.0	52.0
Total Operating Expenses	200.12	291.41	284.10	314.96	403.93	311.09	284.89	747.18	578.16	487.76	646.21	652.94	646.00	712.46	792.45	853.05
Operating Profit	66.95	105.22	60.54	92.17	142.97	92.26	87.13	151.07	111.15	89.45	101.25	98.65	124.24	97.27	134.66	152.17
Operating Margin	25.1	26.5	17.6	22.6	26.1	22.9	23.4	16.8	16.1	15.5	13.5	13.1	16.1	12.0	14.5	15.1
Financing Income/(Expense) - Net	-0.88	3.22	7.24	1.28	2.52	-6.78	1.73	32.50	29.34	11.95	24.13	4.91	16.19	23.23	21.94	-7.11
Profit before Taxes	79.42	109.48	70.56	96.02	148.19	87.90	63.99	181.91	128.97	104.13	54.17	106.07	116.87	125.64	189.59	201.96
Income Taxes	26.88	49.90	29.53	34.63	48.05	36.38	32.27	55.25	33.71	30.16	31.04	29.34	35.29	35.38	54.86	60.22
Profit after Tax	52.54	57.72	40.99	59.91	82.48	82.05	58.79	123.72	97.27	68.49	15.04	70.86	75.45	84.30	129.13	136.19
PAT Margin	19.7	14.6	11.9	14.7	15.1	20.3	15.8	13.8	14.1	11.9	2.0	9.4	9.8	10.4	13.9	13.5
EPS - Basic - ex Extraordinary Items	5.09	5.60	3.97	5.81	8.00	2.02	0.18	11.99	9.43	6.64	1.46	6.83	7.23	8.02	12.23	12.88
EPS - Diluted - ex Extraordinary Items	5.09	5.60	3.97	5.81	8.00	2.02	0.18	11.99	9.43	6.49	1.43	6.72	7.11	7.95	12.00	12.61
EBIT	66.95	105.22	60.54	92.17	142.97	92.26	87.13	151.07	111.15	89.45	101.25	98.65	124.24	97.27	134.66	152.17
EBITDA	70.59	111.34	71.22	103.47	159.14	112.41	108.52	160.01	123.49	106.68	118.58	117.32	150.62	126.68	168.14	187.39
EBITDA Margin	26.4	28.1	20.7	25.4	29.1	27.9	29.2	17.8	17.9	18.5	15.9	15.6	19.6	15.6	18.1	18.6

Balance Sheet

Abridged

Understanding Balance Sheet

Bliss GVS Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	210	349	352	417	471	566	687	694	770	765	776	697	812	817	946
Long-Term Investments	0	0	0	0	0	1	6	1	2	63	2	55	5	27	31
Property Plant & Equipment - Net	42	93	143	160	190	259	127	182	233	228	295	373	369	418	457
Total Non-Current Assets	100	222	231	245	291	457	173	211	257	312	333	459	402	485	546
Total Assets	310	571	583	662	762	1,023	860	905	1,027	1,077	1,109	1,157	1,214	1,301	1,492
Total Current Liabilities	60	202	190	243	267	437	299	207	231	204	233	193	160	172	236
Long Term Debt	38	91	88	57	38	26	6	33	40	34	27	43	45	33	13
Total Non-Current Liabilities	39	97	96	68	50	33	13	38	46	45	29	46	51	37	25
Total Liabilities	99	299	286	310	316	470	312	245	277	249	262	239	211	209	261
Total Shareholders' Equity	211	258	287	337	413	487	536	646	736	808	819	884	967	1,050	1,193
Minority Interest	0	14	10	15	33	66	11	14	15	20	28	34	36	41	39
Total Equity	211	272	297	352	446	553	548	660	750	828	846	917	1,003	1,092	1,232
Total Liabilities & Equity	310	571	583	662	762	1,023	860	905	1,027	1,077	1,109	1,157	1,214	1,301	1,492

Cash Flow

Abridged

Understanding Cash Flow Statement

Bliss GVS Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	R 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	72.52	73.44	49.07	93.53	115.18	169.23	146.00	222.81	120.29	120.92	65.03	126.37	148.32	166.98	245.21
Working Capital - Increase/(Decrease)	-37.83	-73.94	-19.30	-66.84	-8.33	113.48	-140.80	-183.07	-70.32	-57.89	73.37	-85.12	3.04	-51.46	-104.45
Net CF from Operating Activities	34.69	-0.49	29.77	26.69	106.85	282.71	5.20	39.74	49.97	63.04	138.40	41.25	151.36	115.53	140.76
Capital Expenditures - Net	16.33	17.82	53.73	28.07	13.20	103.46	24.20	38.02	58.40	8.70	72.94	93.11	27.73	72.87	54.30
Net CF from Investing Activities	-24.25	-126.59	-16.25	-33.64	-59.37	-236.78	38.83	-77.25	-55.99	-52.38	-98.86	-20.98	-137.83	-91.88	-55.26
Dividends Paid - Cash - Total	-	8.25	4.89	8.56	6.16	-	7.45	8.24	12.50	5.55	5.33	5.44	5.39	5.45	10.64
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	2.28	2.04	2.31	2.89	1.80
Debt - LT & ST - Issuance/(Retirement) - Total	36.88	115.75	25.07	-10.29	-19.02	-6.53	-19.66	26.62	11.08	-8.93	-17.73	-15.25	-11.75	-20.96	-65.14
Net Cash Flow from Financing Activities	37.41	119.43	8.26	-26.29	-24.63	2.16	-52.14	20.77	-1.48	-14.48	-20.77	-18.64	-14.79	-23.52	-74.28
Free Cash Flow to Equity	55.24	97.43	1.10	-11.66	74.64	172.72	-38.66	28.34	2.64	45.40	47.74	-67.10	111.88	21.69	21.33
Free Operating CF net dividend	18.34	-27.95	-28.86	-10.01	87.39	179.05	-30.46	-12.27	-21.79	48.36	59.07	-57.99	117.63	33.79	73.30
Free Operating CF	18.34	-19.70	-23.97	-1.45	93.54	179.05	-23.02	-4.03	-9.29	53.91	64.40	-52.55	123.03	39.24	83.93

Business Segment Analysis

FY End:

Mar 26

Bliss GVS Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 56.83 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 927.11 Cr

Assets

Pharmaceuticals (100.0%)₹ 1,492.41 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 134.66 Cr

Regional Segment Analysis

FY End:

Mar 26

Bliss GVS Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India. (92.7%)₹ 849.84 CrIndia (7.3%)₹ 67.34 Cr

Historical Segment Analysis

Track how Bliss GVS Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	60	9	74	94	28	76	57

Frequently Asked Questions

What is the revenue of Bliss GVS Pharma Ltd.?

The latest trailing twelve month revenue of Bliss GVS Pharma Ltd. is ₹ 1,005.22 Cr, reflecting a 1-year growth of 20.59% and a 3-year CAGR of 11.64%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Bliss GVS Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Bliss GVS Pharma Ltd. is ₹ 136.19 Cr, with a 3-year earnings CAGR of 30.69%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Bliss GVS Pharma Ltd.?

The trailing twelve month EBITDA of Bliss GVS Pharma Ltd. is approximately ₹ 152.17 Cr (based on an operating margin of 15.14%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Bliss GVS Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Bliss GVS Pharma Ltd. is 12.61. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Bliss GVS Pharma Ltd.?

The debt-to-equity ratio of Bliss GVS Pharma Ltd. stands at 0.02. The interest coverage ratio is 21.39x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Bliss GVS Pharma Ltd.?

The estimated book value per share of Bliss GVS Pharma Ltd. is 112.19 (derived from a P/B ratio of 5.89 and market price of ₹ 660.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Bliss GVS Pharma Ltd.?

The trailing twelve month operating cash flow of Bliss GVS Pharma Ltd. is ₹ 140.76 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Bliss GVS Pharma Ltd. report consolidated or standalone financials?

Bliss GVS Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.